XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized $ 40,134     $ 15,735   $ 120,614 $ 106,367
Drug Product Revenue, Net [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized 1,320     (4,077)   17,701 4,610
Drug Product Revenue, Net [Member] | Japan [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized   $ 14,400 $ 1,700   $ 9,800    
Drug Product Revenue, Net [Member] | Astellas Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized 1,300         17,700  
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Japan [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized 695     (4,313)   16,236 3,297
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Europe [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized $ 625     $ 236   $ 1,465 $ 1,313